Clinical Trial

(TNX-1500) in Kidney Transplant Recipients

Name: (TNX-1500) in Kidney Transplant Recipients — clinical trial record (NCT07204080)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: TONIX-1500

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

The primary objective is to investigate the safety and efficacy of TNX-1500, an FC-modified anti-CD154 mAb, in five kidney transplant recipients at 12 months.

Protocol Amendment History 2 amendments

This ClinicalTrials.gov record has been amended 2 times since 2025-10-01; most recent amendment 2026-02-24.

Trial Details

NCT Number	NCT07204080
Lead Sponsor	Ayman Al Jurdi, MD Collaborators: Tonix Pharmaceuticals, Inc.
Conditions	Kidney Transplant, Kidney Transplant Failure and Rejection, Immunosuppression, Immunosuppression After Kidney Transplantation
Enrollment	5 participants
Start Date	2026-07-01
Primary Completion	2028-09-01 (estimated)
Study Completion	2029-06-30 (estimated)
Updated on ClinicalTrials.gov	2026-02-25